with the introduction of rG-CSFs in the early 1990s, PBPCs for allogeneic transplantation could be collected more conveniently and efficiently. In 1993, the successful use of rG_CSF-mobilised PBPCs for allogeneic transplantation (allogeneic transplant) in a patient wit ALL was reported. Encouragingly, the HLA-compatible donor did not report any adverse effects of rG-CSF therapy or the leukapheresis